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Objective: Vasopressor agents are often prescribed in septic shock. However, their effects 
remain controversial. We conducted a systematic review and Bayesian network meta-analysis 
to compare the effects among different types of vasopressor agents.
Data sources: We searched for relevant studies in PubMed, Embase, and the Cochrane Library 
databases from database inception until December 2014.
Study selection: Randomized controlled trials in adults with septic shock that evaluated 
different vasopressor agents were selected.
Data extraction: Two authors independently selected studies and extracted data on study 
characteristics, methods, and outcomes.
Data synthesis: Twenty-one trials (n=3,819) met inclusion criteria, which compared eleven 
vasopressor agents or vasopressor combinations (norepinephrine [NE], dopamine [DA], 
vasopressin [VP], epinephrine [EN], terlipressin [TP], phenylephrine [PE], TP+NE, TP + 
dobutamine [DB], NE+DB, NE+EN, and NE + dopexamine [DX]). Except for the superiority 
of NE over DA, the mortality of patients treated with any vasopressor agent or vasopressor 
combination was not significantly different. Compared to DA, NE was found to be associated 
with decreased cardiac adverse events, heart rate (standardized mean difference [SMD]: -2.10; 
95% confidence interval [CI]: -3.95, -0.25; P=0.03), and cardiac index (SMD: -0.73; 95% 
CI: -1.14, -0.03; P=0.004) and increased systemic vascular resistance index (SVRI) (SMD: 
1.03; 95% CI: 0.61, 1.45; P0.0001). This Bayesian meta-analysis revealed a possible rank 
of probability of mortality among the eleven vasopressor agents or vasopressor combinations; 
from lowest to highest, they are NE+DB, EN, TP, NE+EN, TP+NE, VP, TP+DB, NE, PE, 
NE+DX, and DA.
Conclusion: In terms of survival, NE may be superior to DA. Otherwise, there is insufficient 
evidence to suggest that any other vasopressor agent or vasopressor combination is superior 
to another. When compared to DA, NE is associated with decreased heart rate, cardiac index, 
and cardiovascular adverse events, as well as increased SVRI. The effects of vasopressor 
agents or vasopressor combinations on mortality in patients with septic shock require further 
investigation.
Keywords: norepinephrine, dopamine, vasopressors, sepsis, shock, network meta-analysis
Introduction
Septic shock is a life-threatening condition and severe sepsis accounts for 20% of 
all admissions to intensive care units.1 Severe sepsis approximates 750,000 cases 
annually in the USA and has a mortality rate averaging 28%.2 For initial resuscitation, 
intravenous fluids are recommended as the first-line therapy. However, vasopressor 
agents are also critical to achieve and maintain adequate blood pressure and tissue 
perfusion, and hence, should be used early.3 Sakr et al4 reported that the most fre-
quently used vasopressor agent during septic shock was norepinephrine (NE, 80.2%), 
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followed by dopamine (DA, 35.4%), and epinephrine (EN, 
23.3%) alone or in combination. Although NE is recom-
mended as the fist-line agent for treating hypotension 
in volume-resuscitated hyperdynamic septic shock,5 the 
second-line vasopressor remains controversial. Previous 
studies have reported that NE may have significant superi-
ority over DA in terms of survival.5–8 However, compared 
with other vasopressors, such as EN, vasopressin (VP), 
terlipressin (TP), and phenylephrine (PE), the outcomes 
on the use of NE were not different. Morelli et al9 reported 
that there was no difference in terms of cardiopulmonary 
performance, global oxygen transport, and regional hemo-
dynamics when PE was administered instead of NE in the 
initial hemodynamic support of septic shock. Russell et al10 
revealed that low-dose VP did not improve survival rates 
in contrast with NE in septic shock patients treated with 
catecholamine vasopressors. Additionally, EN was recom-
mended as an additional agent to NE to maintain adequate 
blood pressure.5 Recently in a single-center randomized 
controlled trial (RCT), NE supplemented by dobutamine 
(DB) was compared to NE supplemented by EN in the 
treatment of septic shock patients.11 However, the effective-
ness of other vasopressor agents or vasopressor combina-
tions as compared to others is limited. Whether the use of 
any vasopressor agents or vasopressor combinations in 
patients with septic shock translates to a survival advantage 
remains unclear. Meta-analyses of vasopressor agents have 
been limited by considering only two or three categories 
of vasopressor agents, not including indirect and direct 
comparisons, and omission of recent RCTs. Therefore, we 
performed a network meta-analysis (NMA) considering 
direct and indirect comparisons of vasopressor agents and 
vasopressor combinations in reducing overall mortality for 
septic shock patients.
Materials and methods
The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA Statement) guidelines were used 
to perform this meta-analysis.12
information sources and eligibility criteria
A search of the PubMed (US National Library of Medicine, 
Bethesda, MD, USA) and Cochrane Library databases and 
Embase from database inception to December 2014 was 
performed. The eligibility criteria were as follows: the study 
design must be randomized controlled, the study must report 
mortality outcome, and the study must evaluate adult patients 
at least 18 years of age.
search strategy
We used text words and medical subject heading (MeSH) 
terms with Boolean strategy. The cross-searching was 
done based on the following three categories: 1) vaso-
pressors related (“vasopressor” or “vasoactive drug” or 
“catecholamine” or “pressor agent”); 2) different vasopres-
sors (“norepinephrine” or “dopamine” or “epinephrine” or 
“adrenaline” or “isuprel” or “aleudrin” or “vasopressin” or 
“terlipressin” or “phenylephrine” or “dopexamine”); 3) dis-
ease (“sepsis” or “infection” or “septic shock” or “shock” or 
“systemic inflammatory response syndrome” or “SIRS”). The 
search was limited to the “English” language and “human” 
subjects. Further search by reviewing conference proceedings 
and the references of review articles was performed manu-
ally if necessary.
study selection
Two independent investigators (FZ and ZM) performed 
the study selection. Differences between the two investiga-
tors were resolved by consensus or adjudicated by a third 
investigator (XZ). Agreement between the two reviewers 
on study inclusion was excellent (k=1). Studies on adult 
patients with septic shock that evaluated the mortality rates 
of different vasopressor agents or vasopressor combinations 
were selected.
Data extraction
Two investigators independently extracted raw data using 
a standard form for each study. The form included year 
of publication, the study type, number of patients, patient 
characteristics, and details of the outcomes. The main 
outcome was 28-day mortality. We used the mortality rate 
from the only undetermined time point or the nearest time 
point when mortality was reported at only an undetermined 
time point or several time points, respectively. In addition, 
we also assessed cardiac adverse events and hemodynamic 
and metabolic parameters.
Quality assessment
We assessed the quality of each study selected for this 
meta-analysis by using the Jadad score, which includes the 
following criteria: randomization, concealment of treatment 
allocation, clinician blinding, baseline balance between 
groups, and the description of withdrawals and dropouts.13
statistical analysis
A meta-analysis was performed to calculate direct estimates 
of treatment effect for each pair of vasopressor agents or 
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vasopressor combinations. According to heterogeneity of 
treatment effect across trials using the I2-statistics,14 a fixed-
effect model (P0.1) or random-effects model (P0.1) was 
used. Results in terms of odds ratio (OR) for dichotomous 
outcomes or standardized mean difference (SMD) for con-
tinuous data were expressed with mean and 95% confidence 
intervals (CIs). The direct meta-analysis was done using 
Review Manager, version 5.1.2 (RevMan; The Cochrane 
Collaboration, Oxford, UK).
Using a Bayesian framework, we performed random-
effects NMAs for each vasopressor agent or vasopressor 
combination. NMA is a recent emerging approach used to 
evaluate the effect size of all possible pairwise compari-
sons even if they are not compared head-to-head.15 Results 
such as ORs are expressed with 95% CIs. These CIs from 
NMAs are the Bayesian analogs of the 95% CIs.15 The 
models had 80,000 iterations, while a burn-in of 40,000 
and a thin of 10 were used.16 Vague priors were used.16 All 
convergence on the basis of Brooks–Gelman–Rubin plots 
was assessed.16 Cumulative probability plot (cumulative 
probability vs rank curve) is presented. Using R-project 
3.1.1, the Z-test was conducted to assess for inconsistency 
of triangular loops.17 Area under the cumulative probability 
curve represents the rank of probability. The analysis for 
the NMA was performed using WinBUGS1.4.3 (Medical 
Research Council Biostatistics Unit; www.mrc-bsu.cam.
ac.uk/software/bugs/) and R-project 3.1.1 (http://cran.r-
project.org/). Publication bias was tested by funnel plots 
whenever possible.
Results
study selection
There were 4,280 potentially relevant studies, and 49 articles 
were retrieved for detailed assessment. Twenty-eight articles 
were excluded because there were no mortality comparisons 
(n=20), no sepsis patients (n=2), other septic shock inves-
tigations (n=3), and post hoc analyses (n=3). Twenty-one 
studies were included in this meta-analysis (Figure 1).9–11,18–35 
To evaluate hemodynamic outcomes, we extracted heart 
rate (HR), mean arterial pressure (MAP), systemic vascular 
3RWHQWLDOO\UHOHYDQWVWXGLHVLGHQWLILHGE\VHDUFK 3XE0HGQ  (PEDVHQ  &RFKUDQHQ 
&LWDWLRQVH[FOXGHGDIWHUVFUHHQLQJRIWLWOHDEVWDUFW 1RWUHOHYDQW 3DWLHQWVKDGRWKHUGLDJQRVHV 'XSOLFDWH
&LWDWLRQVH[FOXGHGDIWHUVFUHHQLQJRIIXOOWH[W 1RFRPSDULVRQRIPRUWDOLW\ 1RSDWLHQWVZLWKVHSVLV 7KHRWKHUUHVHDUFKRIVHSWLFVKRFN 3RVWKRFDQDO\VLV
&LWDWLRQVVHOHFWHGIRUPRUHGHWDLOHGHYDOXDWLRQ
6WXGLHVLQFOXGHGLQWKHPHWDDQDO\VLV
Figure 1 Quorum chart of study cohort.
Note: The search had been conducted using the PubMed, embase, and the Cochrane library databases from database inception to December 2014.
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resistance index (SVRI), cardiac index, and mortality data 
from studies by Russell et al10 and Gordon et al.30
study characteristics
Fourteen single-center9,11,18–24,26,29,31,32,34 and seven mul-
ticenter studies10,25,27,28,30,33,35 were identified. The char-
acteristics and inclusion criteria of the selected RCTs 
are summarized in Table 1. These articles were reported 
between 1993 and 2012, and a total of 3,819 patients 
were included in this study. Inclusion criteria were not 
the same for all trials; however, all patients met the diag-
nosis of severe sepsis or septic shock (Table 1).36 Mean 
age ranged from 18 years to 70 years, and the proportion 
of male patients ranged from 46% to 77.3%. The mean 
Acute Physiology and Chronic Health Evaluation II 
(APACHE II) score was 23.8.
All studies evaluated the vasopressor effects in 
patients with septic shock by using a primary outcome 
such as survival, hemodynamics, or APACHE II score 
(Table 2). Vasopressor agents include NE,9,10,18–20,23,25,26,28–35 
EN,21,22,24,27,28 VP,10,25,30,31,33 DA,18–20,26,34,35 TP,23,31 PE,9,32 
NE+DB,11,21,22 NE+EN,11 TP+NE,9 TP+DB,9 and NE + 
dopexamine (DX) (Table 2, Figure 2).24 The mortality data 
from the RCT by De Backer et al7,35 were extracted from 
their meta-analysis.
Risk of bias within studies
Only RCTs were included in the analysis. Sequence of ran-
domized allocation was reported in all but two studies.22,34 
Blinding was conducted in nine studies.9–11,20,27,30,32,33,35 
The mean Jadad score was 3.3.
effect of different vasopressor agents 
on mortality
Mortality in these 21 trials was 50.1% (1,915/3,819). When 
compared to NE, DA was associated with increased mor-
tality (OR: 1.24, 95% CI: 1.01, 1.53). However, there was 
no significant difference in mortality in direct or indirect 
comparisons between other different vasopressor agents and 
vasopressor combinations (P0.05) (Figure 3). For the prob-
ability of mortality, the possible rank from low to high was 
NE+DB (area under the curve [AUC]: 0.2648), EN (AUC: 
0.3473), TP (AUC: 0.379), NE+EN (AUC: 0.3943), TP+NE 
(AUC: 0.3967), VP (AUC: 0.4212), TP+DB (AUC: 0.5423), 
NE (AUC: 0.5752), PE (AUC: 0.6796), NE+DX (AUC: 
0.7279), and DA (AUC: 0.7718) (Figures 4 and 5). The tests 
of inconsistency for the two triangular closed loops were not 
significant (Figure 6). This meant that direct and indirect 
estimates had similar effects in the closed loop.15,17
effect of different vasopressor agents 
on cardiac adverse events
Included studies compared NE vs DA, NE vs VP, NE vs TP, 
NE vs PE, TP+NE vs TP+DB, and TP+DB vs EN directly. 
We performed direct meta-analysis of cardiac adverse events, 
which mainly consisted of arrhythmias and tachycardia. NE 
decreased cardiac adverse events significantly compared to 
DA (Table 3). No significant difference in cardiac adverse 
events was found between other vasopressor agents and 
vasopressor combinations.
effect of different vasopressors on 
hemodynamic and metabolic parameters
Thirteen studies reported that there were significant dif-
ferences in the effect on hemodynamics,10,11,18,20,22–26,29–32 
and eleven studies reported that there were significant 
differences on metabolic parameters or organ function 
between vasopressor agents and vasopressor combinations 
(Table 2).11,18–22,24–26,29,31,33
Four trials with complete data compared the treatment of 
NE and DA.18–20,26 The results revealed that NE decreased HR 
(SMD: -2.10; 95% CI: -3.95, -0.25; P=0.03) and cardiac 
index (SMD: -0.73; 95% CI: -1.14, -0.03; P=0.004) and 
increased SVRI (SMD: 1.03; 95% CI: 0.61, 1.45; P0.0001), 
but there was no significant difference on MAP, oxygen 
delivery (DO
2
), oxygen consumption (VO
2
), and lactate. In 
contrast, as compared to NE, VP significantly decreased HR 
(SMD: 0.21; 95% CI: 0.07, 0.34; P=0.003).
Compared to the NE+DB combination, EN did not show 
a significant difference in HR, MAP, cardiac index, pulmo-
nary MAP, DO
2
, VO
2
, and lactate (Table 4). However, the 
NE+EN combination was more effective than the NE+DB 
combination in reversing the abnormalities of cardiovascular 
parameters, and the NE+EN group had significantly higher 
MAP, HR, CVP, cardiac index, SVRI, ejection fraction, left 
ventricular end diastolic volume, DO
2
, lactate, and urine 
output.11
Discussion
Twenty-one trials that included 3,819 patients and that 
compared different vasopressor agents or vasopressor 
combinations in septic shock were identified and included 
in this systematic review and NMA of RCTs. The trials’ 
mean Jadad score was 3.3, which means that they were of 
high quality. The main results showed that except for the 
superiority of NE over DA in direct comparison, the mor-
tality of patients treated with any other vasopressor agent 
or vasopressor combination was not significantly different. 
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Figure 2 network of eligible comparisons for the multiple-treatment meta-analysis 
for mortality.
Notes: The width of the lines is proportional to the number of trials comparing 
each pair of treatments, and the size of each node is proportional to the number 
of randomized participants (sample size). The network of eligible comparisons for 
acceptability (dropout rate) analysis is similar.
Abbreviations: Da, dopamine; DB, dobutamine; DX, dopexamine; en, epinephrine; 
ne, norepinephrine; Pe, phenylephrine; TP, terlipressin; VP, vasopressin.
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Figure 3 Mortality of different vasopressors in direct comparison and network meta-analysis in terms of mortality. 
Notes: Results are the ORs and CIs in the row-defining treatment compared with the ORs and CIs in the column-defining treatment. For mortality, ORs 1 favor the row-
defining treatment. Network meta-analysis results are at the bottom-left of the figure, while direct comparison results are at the upper-right of the figure. 
Abbreviations: CI, confidence interval; DA, dopamine; DB, dobutamine; DX, dopexamine; EN, epinephrine; NE, norepinephrine; NMA, network meta-analysis; OR, odds 
ratio; Pe, phenylephrine; TP, terlipressin; VP, vasopressin.
NE was also associated with decreased cardiac adverse 
events, HR, and cardiac index, as well as increased SVRI, 
as compared to DA.
Our meta-analysis revealed a possible rank of prob-
ability of mortality among the eleven vasopressor agents 
or vasopressor combination; from low to high, they are 
NE+DB, EN, TP, NE+EN, TP+NE, VP, TP+DB, NE, PE, 
NE+DX, and DA. However, variations in each RCT’s 
inclusion criteria may have influenced the probability of 
mortality. Thus, this ranking should be interpreted with 
caution.
Our NMA evaluated the vasopressor agents or vasopres-
sor combinations from both direct and indirect comparisons. 
This approach differs from traditional head-to-head meta-
analysis. Some traditional meta-analyses of RCTs have 
compared only two or three vasopressor agents, such as NE, 
DA, and VP.10,35 However, other types of comparisons have 
never been performed. This NMA compared any vasopressor 
agent or vasopressor combination to others and revealed a 
possible rank of probability of mortality.15
Three factors support the internal validity of our 
analysis. First, a rigorous and extensive literature search 
was conducted, and the number of selected studies was more 
than any in previous meta-analyses focusing on vasopres-
sor agents and vasopressor combinations for the treatment 
of septic shock. Second, the selected trials are considered 
high-quality studies, with a mean Jadad score of 3.3 points. 
Third, tests of inconsistency for triangular loops were not 
significant; in other words, the direct and indirect estimates 
had similar effects. This finding supports that our NMA has 
adequate homogeneity, which translates to more confidence 
in support of the results.
Vasopressor therapy is recommended by every major 
clinical practice guideline when fluid resuscitation fails 
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Table 3 Direct comparison of different vasopressors on cardiac adverse events
Number  
of studies
Number  
of patients
OR (95% CI) Heterogeneity I2  
(P-value)
Test for effect 
(P-valuea)
ne vs Da 134 252 0.15 (0.05, 0.43) – 0.0005
ne vs VP 310,25,31 831 1.30 (0.73, 2.32) 0% (0.48) 0.38
ne vs TP 131 30 12.13 (0.59, 248.49) – 0.11
ne vs Pe 19 32 0.47 (0.04, 5.73) – 0.55
TP+ne vs TP+DB 127 330 0.88 (0.53, 1.45) – 0.61
TP+DB vs en 111 60 0.66 (0.18, 2.36) – 0.52
Note: aFixed-effect model.
Abbreviations: CI, confidence interval; DA, dopamine; DB, dobutamine; EN, epinephrine; NE, norepinephrine; PE, phenylephrine; TP, terlipressin; VP, vasopressin; 
vs, versus.
DFG
DIJ
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± ± ±    
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±
Figure 6 inconsistency for triangular loops.
Notes: acd: norepinephrine, vasopressin, and terlipressin comparison closed loop; afg: norepinephrine, terlipressin + dobutamine, and terlipressin + norepinephrine 
comparison closed loop. The values are shown as mean (confidence interval of inconsistency estimate). The symbol  indicates sample size.
to maintain adequate blood pressure and organ perfusion. 
However, different vasopressor agents and vasopressor com-
binations increase blood pressure through different mecha-
nisms, leading to heterogeneity of physiological effects.37 
NE is the first-line vasopressor agent used to treat septic 
shock (grade 1B)5 and is associated with lower mortality 
compared to DA.6,7 Although the typical order for the addi-
tion of vasopressor agents is NE, epinephrine, VP, DA, and 
PE,38 the supporting evidence for this order is limited except 
for the superiority of NE over DA in terms of mortality.6,7 
NE supplemented with EN is the second choice in treating 
septic shock (grade 2B).5 In this meta-analysis, only one 
study reported NE+EN vs NE+DB.11 The rank of probability 
of mortality revealed that NE+EN had lower risk than NE. 
VP is neither recommended nor suggested (grade UG) but 
can be added to NE with the intent of either raising MAP 
or decreasing NE dosage.5,38 PE, which is used to stimulate 
purely α-1 receptors, is recommended when cardiac output is 
known to be high and the target blood pressure is not achieved 
(grade 1C).5 No significant difference between PE and other 
vasopressor agents or vasopressor combinations was found. 
Similar results were also found in the comparison between 
other vasopressor agents or vasopressor combinations. 
Recently, a trial compared the vasopressor effects of NE+DB 
and NE+EN on the cardiovascular support of patients with 
septic shock.11 To better evaluate any mortality benefit from 
the initial vasopressor used, we also compared vasopressor 
combinations of NE+DB, TP+NE, TP+DB, NE+EN, and 
NE+DX. The results showed that the vasopressor combina-
tion NE+DB had the lowest probability of mortality, and this 
finding may be supported by the rapid normalization of both 
gastric–arterial difference (PCO
2
 gap) and gastric intramu-
cosal pH.22 No other vasopressor combination is superior to 
another in both direct and indirect comparisons.
For cardiac adverse events and hemodynamic and 
metabolic parameters, we conducted only direct comparisons 
because the small number of studies failed to form an effec-
tive network analysis loop. Our direct meta-analysis revealed 
that cardiac adverse events, HR, and cardiac index were 
decreased and SVRI was increased on treatment with NE 
compared to the results of treatment with DA. These results 
support the notion that NE may have stronger α-receptor 
effects, resulting in a greater increase in SVRI and blood 
pressure as compared to DA.4,39 Even though some stud-
ies favored NE as the more effective vasopressor agent to 
maintain adequate MAP during septic shock, no significant 
difference in terms of effect on MAP between these two 
vasopressor agents has ever been detected.20,40 Overall, NE 
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Table 4 Direct comparison of different vasopressors on hemodynamic and metabolic parameters
Number  
of studies
Number  
of patients
SMD IV (95% CI) Heterogeneity I2  
(P-value)
Test for effect 
(P-value)
ne vs Da
hR 418–20,26 105 -2.10 (-3.95, -0.25) 91% (0.0001) 0.03a
MaP 318–20 55 0.64 (-1.09, 2.38) 87% (0.0004) 0.47a
Cardiac index 418–20,26 105 -0.73 (-1.14, -0.03) 43% (0.15) 0.004b
sVRi 418–20,26 105 1.03 (0.61, 1.45) 26% (0.25) 0.0001b
DO2 4
18–20,26 105 -0.54 (-1.50, 0.42) 79% (0.003) 0.27a
VO2 4
18–20,26 105 -0.49 (-1.37, 0.39) 75% (0.008) 0.27a
lactate 318–20 55 0.01 (-0.53, 0.56) 23% (0.27) 0.96b
ne vs VP
hR 310,25,31 831 0.21 (0.07, 0.34) 0% (0.96) 0.003b
MaP 310,25,31 831 -0.07 (-0.21, 0.07) 0% (0.70) 0.76b
Cardiac index 325,30,31 294 -0.04 (-0.26, 0.19) 0% (0.93) 0.76b
sVRi 225,31 53 0.15 (-0.39, 0.70) 0% (0.91) 0.58b
DO2 2
25,31 53 -0.06 (-0.62, 0.49) 0% (0.42) 0.82b
VO2 2
25,31 53 0.03 (-0.52, 0.59) 0% (0.44) 0.91b
lactate 225,31 53 0.25 (-0.31, 0.80) 0% (0.95) 0.38b
ne+DB vs en
hR 221,22 52 0.33 (-0.22, 0.89) 49% (0.16) 0.24b
MaP 221,22 52 -0.24 (-0.78, 0.31) 0% (0.99) 0.90b
Cardiac index 221,22 52 -0.04 (-0.59, 0.51) 48% (0.17) 0.90b
MPaP 221,22 52 -0.09 (-0.63, 0.45) 0% (0.71) 0.75b
DO2 2
21,22 52 -0.19 (-0.74, 0.36) 47% (0.17) 0.50b
VO2 2
21,22 52 -0.13 (-0.67, 0.42) 0% (0.41) 0.65b
lactate 221,22 52 -0.11 (-0.66, 0.43) 0% (0.59) 0.69b
Notes: aRandom-effects model; bfixed-effect model.
Abbreviations: CI, confidence interval; DA, dopamine; DB, dobutamine; DO2, oxygen delivery; en, epinephrine; hR, heart rate; iV, inverse variance method; MaP, mean 
arterial pressure; MPaP, mean pulmonary arterial pressure; ne, norepinephrine; sMD, standardized mean difference; sVRi, systemic vascular resistance index; VO2, oxygen 
consumption; VP, vasopressin; vs, versus.
is probably more effective than DA in hemodynamic support 
for septic shock patients.
A previous trial reported that VP might increase SVRI 
and decrease cardiac index compared to baseline, while 
NE did not.25 Meta-analysis that included two trials failed 
to find any significant difference in cardiac adverse events 
as well as hemodynamic and metabolic parameters between 
NE and VP.
Statistically, with 80% power and two-sided alpha level 
of 0.04, to detect a 15% relative difference in 28-day mortal-
ity rate, at least 765 subjects in each group were needed.35 
In the present meta-analysis, only “NE vs VP” (n=1,799) 
and “NE vs DA” (n=1,408) comparisons had potentially 
adequate sample size.
limitations
Our analysis has many limitations. First, only English lan-
guage articles were included in this study, which may have 
affected the findings due to selection bias. Second, although 
21 trials were included in this study, the actual sample size 
population in specific comparisons was small, and the risk of 
false attribution of positive effect from pooling small trials is 
well known. Moreover, differences in each RCT’s inclusion 
criteria may have influenced the probability of mortality. 
Additionally, publication bias analysis could not be con-
ducted. Hence, we do not think that these results constitute 
a reason to change clinical practice, but rather, they support 
the need for further investigations.
Conclusion
In terms of survival, NE may be superior to DA. Otherwise, 
there is insufficient evidence to suggest that any other 
vasopressor agent or vasopressor combination is superior 
to another. When compared to DA, NE is associated with 
decreased cardiac adverse events, HR, and cardiac index, as 
well as increased SVRI. The effects of vasopressor agents 
or vasopressor combinations on patients with septic shock 
require further investigation by larger-scale RCTs.
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